On Monday, Paris-based French drugmaker Sanofi announced plans to invest more than €1 billion at three facilities in France to create new bioproduction capacity.
The new investment is expected to create more than 500 jobs and significantly strengthen France’s ability to control the production of essential medicines from start to finish, the company stated. According to Sanofi, this plan increases the amount Sanofi has committed to major projects in France since the Covid-19 pandemic to over €3.5 billion.
In Vitry-sur-Seine, Sanofi wants to invest €1 billion to build a new facility that will double the site’s monoclonal antibody production capacity, where several biologics in development amongst Sanofi’s pipeline of drugs for the treatment of chronic obstructive pulmonary disorder (COPD), asthma, multiple sclerosis or type 1 diabetes, could be produced.
At the Le Trait site in Normandy, Sanofi plans to invest €100 million to expand the capacity for biologics formulation, filling, device assembly and packaging, supporting the launch of future biologics and vaccines, as well as and the further growth of existing biologics production.
In Lyon Gerland, €10 million are to be invested to locate the production of TZield, a biologic for type 1 diabetes that Sanofi acquired in April 2023 and which has been manufactured outside Europe, in France.
Source: chemanager-online.com
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
